Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Desfesoterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.62 |
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.62 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.62 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.62 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.62 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.62 |
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 0.60 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desfesoterodine SCHEMBL28757704 | 0.92 | CHRM3 (0.66) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL580657 | 0.92 | CHRM3 (0.72) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL816124 | 0.92 | CHRM3 (0.72) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL209062 | 0.92 | CHRM3 (0.72) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL29468683 | 0.92 | CHRM3 (0.72) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Fumaric Acid SCHEMBL19212481 | 0.91 | CHRM3 (0.62) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL1808422 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL1808420 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL1811715 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1CHRM3LMNACHRM5 | |
| Desfesoterodine SCHEMBL5178331 | 0.88 | CHRM3 (0.65) | CHRM2CHRM1CHRM3LMNACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2014-12-25 | — | — | US | disclosed |
| WO-2013024415-A1 | AN IMPROVED METHOD FOR THE QUANTITATIVE DETERMINATION OF FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, KLK3, FES | CHRM2 230/4885CHRM3 268/4885HRH1 1613/4885 |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, FES, KLK3 | CHRM2 163/4885CHRM3 146/4885HRH1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.